Breast Cancer Clinical Trial
Official title:
Retrospective Data Collection on the Use of Motiva Flora TE in Breast Reconstruction
The Motiva Flora® TE are intended for temporary subcutaneous or submuscular implantation to develop surgical flaps and additional tissue coverage and are not intended for use beyond six (6) months. All Motiva Flora® TE's require periodic, incremental inflation with sterile saline for injection until the desired tissue amount is developed. After the desired volume, the expander is surgically removed and replaced with a long-term breast implant in the same space as the tissue expander. The study collects retrospective data on the use of the Motiva Flora TE, from patients who had a tissue expander-based-breast reconstruction using the Motiva Flora® TE since market introduction in May 2020.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | September 2024 |
Est. primary completion date | September 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient has completed a tissue expander-based breast reconstruction with the Motiva Flora® TE . - Patient has been informed correctly according to to the applicable national and local regulations. Exclusion Criteria: - Not applicable |
Country | Name | City | State |
---|---|---|---|
Belgium | Dr Filip Stillaert | Ghent |
Lead Sponsor | Collaborator |
---|---|
Establishment Labs |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety - adverse events | Cumulative incidence and causal relationship with the device of adverse events (AEs) reported by the surgeon. This includes known complications as listed in the IFU, as well as any other adverse events, seen as at least possibly related to the device according to the surgeon. | Until finalization of staged Breast reconstruction, approximately 6 months | |
Primary | Safety - device deficiencies | Device-related complications include those resulting from any device failure, including those resulting in removal and/or replacement of the Motiva Flora® TE. | Until finalization of staged Breast reconstruction, approximately 6 months | |
Primary | Performance - succesful implant of long-term breast implant | Successful tissue expander-based-breast reconstruction is measured by the fact that the second step of the staged procedure - the implantation of the long-term breast implant - could be performed or not as initially planned, as per surgeon judgement (Yes / No) | Until finalization of staged Breast reconstruction, approximately 6 months | |
Primary | Performance - surgeon satisfaction | Surgeon's overall satisfaction with the results of the expansion according to the General Aesthetic Improvement Scale (GAIS), a 5-point Likert scale (1=very significant improvement, 2=significant improvement, 3=improvement, 4=no change and 5=decline) after the completion of the breast reconstruction (after the second surgery (long-term breast implant). | Until finalization of staged Breast reconstruction, approximately 6 months | |
Secondary | Length of hospitalization | Length of hospitalization is measured in number of days that the patient stays in hospital after surgery, starting from the day after surgery. | Until discharge from hospital after first surgery (Motiva Flora Tissue Expander), approximately 1-2 days | |
Secondary | Surgical difficulties- 1st surgery (Motiva Flora TE implantation) | Possible difficulties during the during the 1st surgery, measured through the occurrence of: device deficiencies / malfunctions difficulties filling the Tissue expander with the Port Locator |
Intraoperative | |
Secondary | Surgical difficulties - 2nd surgery (Long-term breast implant) | Possible difficulties during the 2nd surgery, measured through the occurrence of: o device deficiencies /malfunctions |
Intraoperative | |
Secondary | Concomitant treatments - 1st surgery | Concomitant treatments during the 1st surgery is measured through the occurrence of: Lipotransfer Latissimus Dorsi Flap |
Intraoperative | |
Secondary | Concomitant treatments - 2nd surgery | Concomitant treatments during the 2nd surgery is measured through the: Use of Motiva Sizers The occurrence of Lipotransfer |
Intraoperative |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |